Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Robert J. Van Gulick"'
Autor:
Victoria M Vorwald, Dana M Davis, Robert J Van Gulick, Robert J Torphy, Jessica SW Borgers, Jared Klarquist, Kasey L Couts, Carol M Amato, Dasha T Cogswell, Mayumi Fujita, Moriah J Castleman, Timothy Davis, Catherine Lozupone, Theresa M Medina, William A Robinson, Laurent Gapin, Martin D McCarter, Richard P Tobin
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 1, Pp n/a-n/a (2022)
Abstract Objectives While much of the research concerning factors associated with responses to immune checkpoint inhibitors (ICIs) has focussed on the contributions of conventional peptide‐specific T cells, the role of unconventional T cells, such
Externí odkaz:
https://doaj.org/article/f3e378fd58ed4a49976a75292f42c335
Autor:
Richard P. Tobin, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S.W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland, William A. Robinson, Martin D. McCarter
Publikováno v:
Clinical Cancer Research. 29:1209-1219
Purpose: A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma. Patients and Methods: Anti–PD-1 naïve patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3102e47fcbe36a3ae8d9339b7052cb6
https://doi.org/10.1158/1078-0432.ccr-22-2495
https://doi.org/10.1158/1078-0432.ccr-22-2495
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
Purpose:A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma.Patients and Methods:Anti–PD-1 naïve patients with st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b6c67c89fc45f804c3ed30132aaba1
https://doi.org/10.1158/1078-0432.c.6532811
https://doi.org/10.1158/1078-0432.c.6532811
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
Characteristics of patients experiencing clinical benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::616d4ce76fe5b82e2a0eb0067a364b89
https://doi.org/10.1158/1078-0432.22494979.v1
https://doi.org/10.1158/1078-0432.22494979.v1
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when the patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::311bb7e612c0c81d35b63683aa70fc69
https://doi.org/10.1158/1078-0432.22494997
https://doi.org/10.1158/1078-0432.22494997
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
Representativeness of study participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15faf811818b1b6f67c522d6373ad277
https://doi.org/10.1158/1078-0432.22494991.v1
https://doi.org/10.1158/1078-0432.22494991.v1
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
All adverse events experienced by patients, including those unrelated to treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33391d10356f03b97e38938e2760c5b5
https://doi.org/10.1158/1078-0432.22488812.v1
https://doi.org/10.1158/1078-0432.22488812.v1
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
Trial inclusion/exclusion criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dbae09a59e1cb85da26bba6ac48af92
https://doi.org/10.1158/1078-0432.22488815.v1
https://doi.org/10.1158/1078-0432.22488815.v1
Autor:
Martin D. McCarter, William A. Robinson, Ross W. McFarland, Rene Gonzalez, Karl D. Lewis, Theresa M. Medina, Eduardo Davila, Dexiang Gao, Kimberly R. Jordan, Kasey L. Couts, Elizabeth Katsnelson, Robert J. Van Gulick, Jessica S.W. Borgers, Dana M. Davis, Victoria M. Cates, Dasha T. Cogswell, Richard P. Tobin
Establishing recommended phase II dose (RP2D) and dose limiting toxicities (DLTs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94b43a89772d92550cc18ada497bd28
https://doi.org/10.1158/1078-0432.22488809
https://doi.org/10.1158/1078-0432.22488809
Autor:
Halis Kaan, Akturk, Kasey L, Couts, Erin E, Baschal, Kagan E, Karakus, Robert J, Van Gulick, Jacqueline A, Turner, Laura, Pyle, William A, Robinson, Aaron W, Michels
Publikováno v:
JAMA Network Open. 5:e2246400
ImportanceTreatment with immune checkpoint inhibitors (ICIs) has increased survival in patients with advanced malignant melanoma but can be associated with a wide range of immune-related adverse events (irAEs). The role of human leukocyte antigen (HL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f835dca462ab3fdfeb9b6d634af5da5b
https://doi.org/10.1001/jamanetworkopen.2022.46400
https://doi.org/10.1001/jamanetworkopen.2022.46400